» Articles » PMID: 10889059

Control of Developmental Timing in Caenorhabditis Elegans

Overview
Publisher Elsevier
Specialties Biology
Genetics
Date 2000 Jul 13
PMID 10889059
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Studies of the nematode Caenorhabditis elegans have identified genetic and molecular mechanisms controlling temporal patterns of developmental events. Mutations in genes of the C. elegans heterochronic pathway cause altered temporal patterns of larval development, in which cells at certain larval stages execute cell division patterns or differentiation programs normally specific for other stages. The products of the heterochronic genes include transcriptional and translational regulators and two different cases of novel small translational regulatory RNAs. Other genes of the pathway encode evolutionarily conserved proteins, including a homolog of the Drosophila Period circadian timing regulator, and a member of the nuclear receptor family of proteins. These regulators interact with each other to elaborate stage-specific regulatory switches and act through downstream effectors to control the timing of cell-type-specific developmental events.

Citing Articles

Thyroid Hormones and Brain Development: A Focus on the Role of Mitochondria as Regulators of Developmental Time.

Vujovic F, Farahani R Cells. 2025; 14(3).

PMID: 39936942 PMC: 11816491. DOI: 10.3390/cells14030150.


Neurogenesis in Caenorhabditis elegans.

Poole R, Flames N, Cochella L Genetics. 2024; 228(2).

PMID: 39167071 PMC: 11457946. DOI: 10.1093/genetics/iyae116.


MicroRNAs: circulating biomarkers for the early detection of imperceptible cancers via biosensor and machine-learning advances.

Metcalf G Oncogene. 2024; 43(28):2135-2142.

PMID: 38839942 PMC: 11226400. DOI: 10.1038/s41388-024-03076-3.


Histone 4 lysine 5/12 acetylation enables developmental plasticity of Pristionchus mouth form.

Werner M, Loschko T, King T, Reich S, Theska T, Franz-Wachtel M Nat Commun. 2023; 14(1):2095.

PMID: 37055396 PMC: 10102330. DOI: 10.1038/s41467-023-37734-z.


Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment.

Zarone M, Misso G, Grimaldi A, Zappavigna S, Russo M, Amler E Sci Rep. 2017; 7(1):17949.

PMID: 29263373 PMC: 5738363. DOI: 10.1038/s41598-017-18186-0.